middle.news
Arovella’s $4.03 million refund clears more room for ALA-101’s first clinical steps
8:43am on Thursday 22nd of October, 2026 AEDT
•
Biotechnology
Read Story
Arovella’s $4.03 million refund clears more room for ALA-101’s first clinical steps
8:43am on Thursday 22nd of October, 2026 AEDT
Key Points
$4.03 million FY2026 R&D Tax Incentive refund received
Cash support for ALA-101 Phase 1 development
ALA-101 is moving towards first-patient dosing
ALA-105 remains on the path towards clinical development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE